Krystal Biotech PT Rises 27% to $284 as Q4 VYJUVEK Revenue Tops $107M
Guggenheim raised Krystal Biotech’s price target to $284 from $224 and maintained a Buy rating after its fiscal Q4 report. Krystal Biotech reported $107.1 million in Q4 VYJUVEK revenue, $389.1 million for FY2025, secured over 660 U.S. reimbursement approvals and ended with $955.9 million in cash.
1. Analyst Price Target Increase
Guggenheim lifted its price target on Krystal Biotech from $224 to $284, representing a 27% increase, and reiterated a Buy rating based on the company’s fiscal Q4 performance and growth prospects.
2. VYJUVEK Revenue Performance
During fiscal Q4, VYJUVEK net product revenue reached $107.1 million, contributing to a total of $389.1 million for full-year 2025, driven by high patient demand and expanding market access in Europe and Japan.
3. Reimbursement and Market Access
Krystal Biotech secured over 660 reimbursement approvals across U.S. payers and noted more than 90 patients prescribed VYJUVEK in Germany, France and Japan, while advancing pricing discussions for a potential Italy launch in H2 2026.
4. Financial Position
The company ended the quarter with a robust balance sheet, holding $955.9 million in cash and investments, providing ample runway to support ongoing commercialization and pipeline developments.